Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use LYTENAVA safely and effectively. See full prescribing information for LYTENAVA. LYTENAVA™ (bevacizumab-vikg) injection, for intravitreal use Initial U.S. Approval: 2026
Medication labelWhy this: Advisory · dailymed-prescription
LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
- generic_name
- bevacizumab-vikg
- product_names
- bevacizumab-vikg
- ndc
- 82491-025, 82491-025-10
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en